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Abstract
Background
Glycoprotein-A Repetitions Predominant protein (GARP or LRRC32) is present on among
others human platelets and endothelial cells. Evidence for its involvement in thrombus for-
mation was suggested by full knockout of GARP in zebrafish.
Objectives
To evaluate the role of GARP in platelet physiology and in thrombus formation using platelet
and endothelial conditional GARP knock out mice.
Methods
Platelet and endothelial specific GARP knockout mice were generated using the Cre-loxP
recombination system. The function of platelets without GARP was measured by flow
cytometry, spreading analysis and aggregometry using PAR4-activating peptide and colla-
gen related peptide. Additionally, clot retraction and collagen-induced platelet adhesion and
aggregation under flow were analyzed. Finally, in vivo tail bleeding time, occlusion time of
the mesenteric and carotid artery after FeCl3-induced thrombosis were determined in plate-
let and endothelial specific GARP knock out mice.
Results
Platelet specific GARP knockout mice had normal surface GPIb, GPVI and integrin αIIb gly-
coprotein expression. Although GARP expression was increased upon platelet activation,
platelets without GARP displayed normal agonist induced activation, spreading on fibrino-
gen and aggregation responses. Furthermore, absence of GARP on platelets did not influ-
ence clot retraction and had no impact on thrombus formation on collagen-coated surfaces
under flow. In line with this, neither the tail bleeding time nor the occlusion time in the carotid-
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and mesenteric artery after FeCl3-induced thrombus formation in platelet or endothelial spe-
cific GARP knock out mice were affected.
Conclusions
Evidence is provided that platelet and endothelial GARP are not important in hemostasis
and thrombosis in mice.
Introduction
The endothelium of the vascular wall prevents thrombus formation by releasing different anti-
coagulant and antiplatelet factors such as nitric oxide and prostaglandin PGI2. Upon endothe-
lial injury, platelets are recruited towards the exposed collagen in the subendothelial matrix.
Platelets rapidly adhere and become activated, resulting among others in alpha-granule release
and activation of integrin αIIbβ3. This leads to the recruitment of additional platelets and
adhesive proteins, and promotes the pro-coagulant activity of both platelets and endothelial
cells, culminating in the formation of a thrombus sealing the injured vessel. However, when
this process is ill-controlled, this may lead to bleeding or the formation of occlusive thrombi
resulting in ischemic cardiovascular events. Only limited pharmaceutical tools are available to
control the thrombotic and hemostatic properties of platelets. Hence, significant efforts are
made towards the identification of unknown platelet and endothelial receptors that could
eventually become therapeutic targets.
The Bloodomics Consortium previously identified uncharacterized platelet receptors
with a possible involvement in thrombosis and hemostasis [1,2]. Gene expression profiles
of human megakaryocytes were compared with those of erythroblasts and different leuko-
cytes using a whole genome microarray. Glycoprotein A Repetitions Predominant protein
(GARP) also known as Leucine Rich Repeat Containing protein 32 (LRRC32), was one of
the receptors newly identified to be present on the megakaryocyte lineage as well as on
endothelial cells [3]. GARP is a 72-kDa glycoprotein that consists of a 13-amino acid cyto-
plasmic tail, a single transmembrane domain and 20 extracellular leucine rich repeats [4,5].
Besides megakaryocytes and endothelial cells, GARP was already known to be present on
activated regulatory T cells (Tregs)[6–8], some fibroblast cell lines [9] and hepatic stellate
cells [10]. The function of GARP is best elucidated for activated Tregs. Although the exact
mechanism is not yet known, GARP expressed on activated Tregs plays a role in surface
presentation of GARP/latent transforming growth factor (TGF)-β1 complexes and in the
release of active TGF-β1 [11]. In platelets, GARP was shown to be co-expressed with latent
TGF-β1 on the cell membrane [6]. Interestingly, involvement of GARP in thrombus forma-
tion was suggested in zebrafish, in which a defect in thrombus growth was observed in the
absence of GARP [3]. Due to the generation of a full GARP knockout zebrafish, it was
indistinguishable whether the obtained results could be explained by GARP expressed on
platelets or on endothelial cells.
The present study aims to further investigate the role of GARP in thrombosis and hemosta-
sis. Transgenic mice lacking GARP expression on platelets and megakaryocytes were gener-
ated using Pf4.Cre mice and on mice lacking GARP expression on endothelial cells using Tie2.
Cre mice. Using these unique mouse strains, the contribution of GARP in thrombosis, hemo-
stasis and thrombo-inflammatory processes was studied by in vitro platelet function assays, as
well as in vivo bleeding, thrombosis and stroke models.
GARP in thrombosis
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Material and methods
Mice
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Pf4 (courtesy
W. Bergmeier, University of North Carolina, Chapel Hill, NC) and Tie2 (courtesy M. Yanagi-
sawa, Southwestern Medical School, Dallas, TX) promotor-driven Cre recombinase transgenic
mice, and mice carrying the Garpfl/fl alleles were described previously [12–14]. Exon 1 of Garpfl/fl
mice is flanked by loxP sites. Excision of exon 1 results in complete disruption of GARP expres-
sion. Pf4 or Tie2 conditional GARP knockout mice (cKO) were generated by first mating mice
carrying the Cre allele driven by the Pf4 or Tie2 promotor with the Garpfl/fl mice. Garpfl/-Cre+/-
mice were backcrossed with Garpfl/fl mice to generate Pf4 or Tie2 specific Garp knockout mice
(cKO, Garpfl/fl Cre+/-) and littermate controls (Garpfl/fl Cre-/-). In experiments, 8 to 12 weeks old
mice were used unless noted otherwise.
Polymerase Chain Reaction (PCR)
Genotypes for loxP, Cre driven by the Pf4 promotor and Cre driven by the Tie2 promotor
were determined with PCR amplification of total genomic DNA obtained after NaOH extrac-
tion of ear samples, using three pairs of primers: 5’-GCAAAGCAGACGGTCATACA-3’,5’-T
CTGGAACTCAAGAGGCTGAG-3’; 5’-GTCCACAGCTGGTGTGGAGA–3’,5’-GGCACCATA
GATCAGGCGGT-3’ and 5’-CGCCGTAAATCAATCGATGAGTTGCTTC–3’,5’-GATGCCGG
TGAACGTGCAAAACAGGCTC-3’, respectively.
Platelet preparation
Platelets were prepared according to standard procedures with minor modifications [15].
Citrated blood (5:1 vol/vol of blood: 3.8% sodium citrate) was taken via the retro-orbital sinus
of mice anesthetized with 5% isoflurane in O2. Blood was diluted (1:1) with HEPES Tyrode
buffer (145 mM NaCl, 2 mM KCl, 0.5 mM NaH2PO4, 5.5 mM glucose, 10 mM HEPES, 1 mM
MgSO4, pH 7.4). Platelet rich plasma (PRP) was obtained via centrifugation at 80 g for 7 min
at room temperature (RT). The remaining blood sample was then centrifuged during 6 min at
2000 g to obtain platelet poor plasma (PPP). For preparation of washed platelets, 1/10 ACD
(85mM sodium citrate, 74mM citric acid, 44μM glucose) was added to the PRP and platelets
were centrifuged at 360 g for 7 min. The pellet was resuspended in HEPES Tyrode buffer pH
6.5, and 1 μM PGE1 and 100 mU apyrase were added before subsequent centrifugation. The
final pellet was resuspended in HEPES Tyrode buffer pH 7.4.
Hematological analysis
Mice were anesthetized with 5% isoflurane/O2 and blood was taken from the retro-orbital
sinus on EDTA (15:1 vol/vol of blood: 0.5M EDTA). Total blood count was performed using
an automated cell counter (Hemavet 1700, Drew Scientific Group, Waterbury, CT). Platelet
count, mean platelet volume, white blood cell (WBC), red blood cell (RBC), hemoglobin (Hb)
and hematocrit (HCT) levels were analyzed.
Platelet aggregometry
Platelet aggregometry was performed as described [16]. The PRP platelet count was normal-
ized to 2.0 x 105 platelets/μL using HEPES Tyrode buffer. Platelet aggregation was monitored
using light transmission in a Chrono-Log dual channel aggregometer (Kordia BV, Leiden, The
Netherlands). PPP was used as a reference. Platelet aggregation was induced by adding 0.75,
2.5 or 5 μg/mL collagen-related peptide (CRP; courtesy RW Farndale, University of
GARP in thrombosis
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Cambridge, Cambridge, UK) or by adding 75, 125 or 250 μM protease activated receptor 4
activating peptide (PAR4-AP; AYPGKF, Bachem, Bubendorf, Switzerland).
Flow cytometry
Platelets. Flow cytometry experiments were performed as described [17]. Briefly, citrated
whole blood was diluted 1:20 in HBS buffer (10 mM HEPES, 150 mM NaCl, 1 mM MgSO4, 5
mM KCl, pH 7.4). Platelets in diluted whole blood were activated by adding 700 μM PAR4-AP
or 20 μg/mL CRP during 20 min at RT before measuring the GARP expression. Platelet activa-
tion with 200 μM PAR4-AP or 2.5 μg/mL CRP was performed to measure the P-selectin
expression on littermate and GARP cKO platelets.
Expression was determined using fluorescently-labeled antibodies against murine GPVI
(JAQ1), CD42c (Xia.C3), P-selectin (Wug.E9), activated integrin αIIbβ3 (JON/A) (all from
Emfret, Eibelstadt, Germany), GARP (REA 139; Miltenyi Biotec, Leiden, The Netherlands)
and CD41 (MwReg30, Biolegend, London, UK). Antibody dilutions were used according to
the manufacturer’s instructions. To measure platelet-fibrinogen binding, diluted blood was
incubated for 20 min at RT with 50 μg/mL FITC-labeled human fibrinogen (Gentaur, Kam-
penhout, Belgium), PE labeled anti-CD41 (MwReg30 Biolegend) and 200 μM PAR4-AP or
2.5 μg/mL CRP. Samples were fixed (0.2% formaldehyde, 154 mM NaCl, pH 7.4) and analyzed
on a FACSVerse flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ).
Endothelial cells. Pieces from livers obtained from mice perfused with PBS buffer (137
mM NaCl, 2.7 mM KCl, 6.5 mM Na2HPO4, 1.5 mM KH2PO4) were digested using 2.5 mg/
mL collagenase A and 20 U/mL DNase. A single cell suspension was made using a 70 μm
nylon filter. GARP expression on endothelial cells was measured in the CD45-CD41-CD31
+ cell population. Expression was determined using fluorescently-labeled antibodies against
murine CD45 (30-F11, eBioscience, Vienna, Austria), CD41 (MwReg30), CD31 (390) and
GARP (REA 139) (both from Miltenyi Biotec). Antibody dilutions were used according to the
manufacturer’s instructions.
Platelet spreading
Spreading of platelets was analyzed as previously described [18]. Briefly, coverslips were coated
overnight with 200 μg/mL human fibrinogen (Sigma Aldrich, Diegem, Belgium). Coated cover-
slips were blocked with 1% BSA in PBS and rinsed with HEPES Tyrode buffer. Washed platelets
were stimulated with 200 μM PAR4-AP or 2.5 μg/mL CRP during 5, 10 and 30 min at RT on
coated coverslips and non-adhering platelets were washed using HEPES Tyrode buffer. Adher-
ent platelets were fixed with 4% PFA and visualized with a Zeiss observed Z.1 inverted micro-
scope (Carl Zeiss, Sliedrecht, The Netherlands). Quantification of platelets was performed by
counting the platelets in different phases of activation: discoid (phase 1), only filopodia (phase
2), filopodia and lamellipodia (phase 3) and fully spread platelets (phase 4).
Clot retraction
Clot retraction experiments were performed as previously described [18]. Briefly, one μL of
erythrocyte suspension was added to 200 μL of citrated PRP in which platelet counts were nor-
malized to 300,000 platelets/μL using PPP. Clot formation was induced with 20 mM CaCl2
and 5 U/mL thrombin (Sigma Aldrich) at 37˚C. Clot retraction was followed over time. Every
2 min, a picture was taken with a digital camera. Clot size was analyzed using ImageJ (version
1.47, NIH, Bethesda, MD).
GARP in thrombosis
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Thrombus formation in flow chambers
Polydimethylsiloxane perfusion chambers were placed on glass coverslips creating a channel
with a height of 75 μm and a width of 2 mm. The channels were coated with 100 μg/mL Horm
collagen (abp, Epsom, UK) for one hour [19]. Heparinized (20 U/ml, LEO Pharma, Wilrijk,
Belgium) whole blood was perfused over the coverslip at a shear rate of 1600 s-1 for 5 minutes.
Before perfusion, blood was incubated with 5 μM Dioc6 (Invitrogen, Ghent, Belgium) during
10 min at 37˚C. Thrombus formation was visualized for 5 min under an Eclipse TE200
inverted fluorescence microscope (Nikon, Tokyo, Japan) coupled to a Hamamatsu CCD cam-
era (ORCA-R2, Hamamatsu Photonics, Hamamatsu, Japan). Aggregate formation was ana-
lyzed as mean percentage platelet coverage of the total area using ImageJ.
Intravital microscopy of FeCl3 injured mesenteric and carotid blood
vessels
Carotid artery thrombosis was induced as previously described [20]. Mice were anesthetized
using a mixture of 2% isoflurane in O2. The blood flow in the right carotid artery was mea-
sured using a flow probe (Transonic TS420 perivascular flowmeter module, AD Instruments,
Paris, France). Thrombus formation was induced by placing a Whatman filter paper saturated
with 12% FeCl3 for 3 min on the surface of the carotid artery, upstream of the flow probe. The
mesenteric thrombosis model was performed as previously described [21]. Mesenteric arteries
of Xylazine/Ketamine anesthetized mice (5 weeks old) were exposed to a Whatman filter paper
saturated with 10% FeCl3 for 2 min. Platelets were fluorescently labeled by intravenous injec-
tion of rhodamine 6G (1 μg/g body weight) (Invitrogen). Thrombus formation in the mesen-
teric artery was followed in real time using an Eclipse TE200 inverted fluorescence microscope
(Nikon) under a 20X objective coupled to a Hamamatsu CCD camera (ORCA-R2, Hamama-
tsu Photonics) [21]. In both models, the occlusion time, defined by a lack of detectable blood
flow after arterial injury, was recorded. The thrombi were followed up during 20 minutes to
monitor the thrombus stability.
Transient middle cerebral artery occlusion
Focal cerebral ischemia was induced in mice by 60 minutes transient middle cerebral artery
occlusion (tMCAO) [20,22]. Mice were anesthetized with 2.5% isoflurane in O2. Following a
midline skin incision in the neck, the proximal right common carotid artery and the external
carotid artery were ligated, and a standardized silicon rubber-coated 6.0 nylon monofilament
was advanced through the right internal carotid artery to occlude the origin of the right MCA.
The intraluminal suture was left in situ for 60 minutes, after which the animals were re-anes-
thetized and the occluding monofilament was withdrawn to allow reperfusion. Twenty-three
hours after reperfusion mice were euthanized to measure cerebral infarct volumes. Brains
were quickly isolated and cut into 2-mm-thick coronal sections using a mouse brain slice
matrix. The slices were stained with 2% 2,3,5-triphenyl-tetrazolium chloride to distinguish
healthy tissue from unstained infarctions. Stained slices were photographed and infarct areas
(white) were measured using Image J software. Edema-corrected infarct sizes were calculated
by use of the following equation: Vcorrected = Vuncorrected x (1 - (Vi—Vc) / Vc) with Vi the
volume of ipsilateral hemisphere and Vc the volume of the contralateral hemisphere.
Ethics statement
Animal experiments were approved by the Institutional Animal Care and Use Committee of
KU Leuven, Leuven, Belgium (Permit Number: P022-2012).
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Statistics
Results are presented as mean ± standard deviation (SD). Statistical significance was assessed
using GraphPad Prism version 5.00 (GraphPad Software, San Diego, CA, USA). ANOVA sta-
tistics was used to measure the GARP expression on platelets. An unpaired t-test was per-
formed to reveal differences between littermates and GARP cKO mice. P-values < 0.05 were
considered significant.
Results
GARP is expressed on murine platelets and is increased after activation
Platelets isolated from C57BL/6J mice were stained for P-selectin and GARP using fluores-
cently-labeled antibodies. Flow cytometric analysis of stained platelets revealed that GARP is
expressed on resting murine platelets. The resting status of the platelets is confirmed by the
absence of P-selectin on the surface. Furthermore, when platelets were activated by PAR4-AP,
not only P-selectin expression was increased, as expected, but interestingly, also the GARP
expression was increased 2.2 fold (Fig 1A). Similarly, GARP expression levels on the platelet
Fig 1. Generation of platelet specific GARP knockout mice. GARP and P-selectin expression on 700 μM PAR4-AP (A)
or 20 μg/mL CRP (B) activated murine platelets. Mean fluorescence intensity (MFI) of anti-GARP-APC and anti-P-selectin
CD62P-PE are shown. (C) Genotypic analysis of genomic DNA from control C57BL/6, littermates and platelet specific cKO
mice. Loxp is 181 bp (fl/fl); wt allele is 111 bp, Cre 250 bp. (D) Phenotypic characterization of littermates and cKO mice using
flow cytometry. Platelets were labeled with anti-CD41-FITC and anti-GARP-APC and a histogram was made based on APC
intensity of CD41+ cells: isotype control (black line), littermates (grey line) and cKO (black).
doi:10.1371/journal.pone.0173329.g001
GARP in thrombosis
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surface were increased 1.34 fold upon activation with CRP, although this increase was not sig-
nificant (Fig 1B).
Platelet specific GARP knockout mice have normal blood cell counts and
normal levels of GPIb, GPVI and integrin αIIb glycoprotein on their
platelet surface
The CMV promotor driven Cre recombinase was used to generate full GARP knockout mice.
As however mice expressing the Cre recombinase and being homozygous for the deleted Garp
allele had an embryonic lethal phenotype (S1 Fig), we next specifically knocked down GARP
on platelets by site specific recombination using the Pf4 promoter driven Cre recombinase to
generate GARP cKO (loxP+/+ Cre+/-) and littermates (loxP+/+ Cre -/-). The genotyping of
C57BL/6 mice, littermates and GARP cKO mice demonstrates the presence of loxP sites (181
bp) and the Cre recombinase (250 bp) in the genomic DNA (Fig 1C). Correct recombination
was confirmed by demonstrating the absence of GARP on platelets of Pf4 specific GARP
knockout mice by flow cytometry (Fig 1D). The platelets of Pf4 specific GARP knockout mice
did not show overall abnormalities as the platelet volume and expression levels of the surface
glycoproteins GPIb, GPVI and integrin αIIb were unaltered. Additionally, no significant dif-
ferences were found in platelet, WBC and RBC counts, and Hb and HCT levels between litter-
mates and GARP cKO mice (Table 1). The platelet specific GARP knockout mice were born at
the expected Mendelian inheritance, showed no discernible phenotype, were fertile and their
body weights were comparable to controls.
GARP deficiency in platelets does not affect platelet activation and
spreading
Since the GARP expression on mouse platelets is increased after activation and as previous
experiments in zebrafish suggested that GARP is implicated in thrombus formation [3], we
next studied the effect of GARP deficiency on in vitro platelet activation. First, platelets from
GARP cKO and littermates were stimulated with 200 μM PAR4-AP or 2.5 μg/mL CRP and
activation was assessed via flow cytometry by measuring expression of P-selectin and activated
integrin αIIbβ3, as well as fibrinogen binding. As expected, platelet activation with PAR4-AP
(Fig 2A, 2C and 2E) and CRP (Fig 2B, 2D and 2F) resulted in increased P-selectin expression
(Fig 2A and 2B), increased activation of integrin αIIbβ3 (Fig 2C and 2D) and an increased
Table 1. GARP cKO platelets are well formed and GARP cKO mice display unaltered hematological parameters.
Pf4 GARP+/+ Pf4 GARP cKO P-value
GPIb (MFI ± SD) 5445 ± 181 5345 ± 194 n.s.
GPVI (MFI ± SD) 527 ± 22 583 ± 31 n.s.
αIIb (MFI ± SD) 2.297 ± 1.099 x 104 2.426 ± 0.765 x 104 n.s.
PLT Vol. (fL) 5.52 ± 0.23 4.63 ± 0.25 n.s.
PLT X 10/μL 684.5 ± 82 659.0 ± 75 n.s.
WBC X 10/μL 7.11 ± 1.53 6.58 ± 2.22 n.s.
RBC X 106/μL 8.95 ± 1.08 8.95 ± 1.11 n.s.
Hb (g/dL) 11.40 ± 1.07 11.43 ± 1.61 n.s.
HCT (%) 42.07 ± 4.95 42.97 ± 6.29 n.s.
Platelet receptors are quantified as mean fluorescence intensity (MFI) ± SD; n = 3; Platelet volume (PLT Vol.); platelet (PLT); white blood cell (WBC)and red
blood cell (RBC) count, hemoglobin (Hb) and hematocrit (HCT) levels; data are expressed as mean ± SD; n = 10; n.s. non-significant.
doi:10.1371/journal.pone.0173329.t001
GARP in thrombosis
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fibrinogen binding (Fig 2E and 2F). Absence of GARP on platelets did not affect P-selectin
expression and fibrinogen binding (Fig 2A, 2B, 2E and 2F), however a slightly but significantly
(P = 0.04) lower activation of integrin αIIbβ3 was observed in the cKO platelets compared to
control platelets after stimulation with CRP (Fig 2D).
When platelet activation is initiated, platelets undergo morphologic changes as a result of
actin skeleton reorganization. On fibrinogen-coated surfaces, this results in a transformation
from discoid shaped- to fully spread platelets. To verify if GARP is involved in this process,
platelets were stimulated with 200 μM PAR4-AP (Fig 2G) or 2.5 μg/mL CRP (Fig 2H). Filopo-
dia and lamellipodia are formed in the GARP cKO mice to the same extent as in the littermate
Fig 2. GARP expression is elevated upon platelet activation but does not affect outside-in and inside-out signaling. MFI of P-selectin
(anti-CD62P-PE) (A-B), JON/A (anti-GPIIbIIIa-PE) (C-D) and fibrinogen binding (E-F) to unactivated or 200 μM PAR4-AP (A-C-E) or 2.5 μg/mL
CRP (B-D-F) activated platelets of littermates and cKO mice are measured using flowcytometry. Platelets were gated based on CD41 (anti-
CD41-FITC) expression. Graphs show mean ± SD, n = 3. Washed platelets of littermates and cKO mice were allowed to spread on 100 μg/mL
fibrinogen while activated with 200 μM PAR4-AP (G) or 2.5 μg/mL CRP (H) during 5, 10 or 30 min. Platelets are divided in different phases of
activation (1) round, (2) only filopodia, (3) filopodia and lamellipodia, (4) fully spread. (I) Representative images of platelet spreading; scale bars
represent 5 μm.
doi:10.1371/journal.pone.0173329.g002
GARP in thrombosis
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controls (representative images are shown in Fig 2I). All together, these results demonstrate
that GARP is not involved in the activation of platelets although GARP expression is increased
after activation.
GARP deficiency in platelets does not affect platelet aggregation, clot
retraction nor platelet adhesion on collagen
To further assess the potential effect of GARP on platelet function, we performed aggregations
with PRP from GARP cKO mice and littermates. Platelet aggregation was induced via a G pro-
tein-coupled receptor-mechanism by PAR4-AP or via Tyr-phosphorylation by CRP using a
low, intermediate and high concentration of each agonist. GARP deficient platelets aggregated
in a similar fashion compared to their littermate controls in response to both PAR4-AP (Fig
3A) and CRP (Fig 3B). Representative tracings of aggregations induced by 125 μM PAR4-AP
and 1.25 μg/mL CRP are shown in Fig 3B and 3D, respectively. In line with platelet activation,
no difference in aggregation was observed between platelets with and without GARP (Fig 3B
and 3D).
As we did not observe a role for GARP in either platelet activation, spreading or aggregate
formation, we questioned whether GARP might be involved in the next phase of thrombus for-
mation being clot retraction. After an aggregate is formed, platelets will contract their cytoskel-
eton. This mechanism affects the fibrin network bound to integrin αIIbβ3 and reduces the
volume of the clot. To initiate thrombus formation and subsequent clot retraction, thrombin
and CaCl2 were added to PRP of littermates and GARP cKO mice. The clot retraction was fol-
lowed for 30 min and a gradual decrease in clot volume was measured (Fig 3E; quantification
on left, representative images on right). Again, GARP cKO mice did not show an altered clot
volume over time compared to littermates, which indicates that platelet GARP is not involved
in clot retraction.
All experiments performed thus far were performed under static or rotational flow condi-
tions and did not incorporate shear stress. Therefore, we next performed perfusions over colla-
gen-coated surfaces to examine the potential role of platelet GARP in thrombus formation
under flow. Platelets in whole blood were labeled with Dioc6, and then perfused at an arterial
shear rate of 1600 s-1. Platelets adhered readily to collagen and subsequent platelet aggregate
formation was followed for 5 min. The surface coverage was quantified and demonstrated no
difference between GARP cKO mice and littermates (Fig 3F; quantification on left, representa-
tive images on right), indicating that GARP does not influence platelet adhesion and aggrega-
tion under arterial shear stress.
Platelet specific GARP cKO mice display normal tail bleeding, FeCl3-
induced thrombosis and infarct volume after ischemic stroke
As the ex vivo assays could not indicate a role for GARP in platelet function, we next investi-
gated whether GARP is involved in physiological hemostasis and thrombosis using in vivo
mouse models. First, we performed a tail clip bleeding time assay (Fig 4A), which revealed that
the average bleeding time of littermates was not significantly different from that of the GARP
cKO mice. In parallel, we assessed the involvement of platelet-specific GARP in arterial throm-
bus formation in well-established carotid and mesenteric FeCl3-induced arterial thrombosis
models [21]. In the carotid artery, occlusive thrombus formation was monitored using a Dopp-
ler flow probe for up to 20 min post injury. In this model both littermates and GARP cKO
mice did form occlusive thrombi at a similar rate (Fig 4B). In mesenteric arteries, occlusive
thrombus formation was measured by real time imaging of the thrombus after fluorescent
labeling of the platelets. Complete vessel occlusion was comparable for GARP cKO mice and
GARP in thrombosis
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Fig 3. GARP deficiency in platelets does not affect platelet aggregation. Aggregation was induced in PRP of GARP+/+ and GARP cKO mice
using 75, 125 or 250 μM PAR4-AP (A) and 0.75, 2.5 or 5 μg/mL CRP (C). Maximal light transmission was calculated and graphed of at least 3
individual experiments. Representative curves for 125 μM PAR4-AP (B) and 2.5 μg/mL CRP (D) induced aggregations in GARP+/+ (grey) and GARP
cKO (black) are shown. (E) Clot retraction of PRP supplemented with erythrocytes was induced using 5 U/mL thrombin and 20 mM CaCl2 in GARP+/+
littermates and GARP cKO. Pictures were made every two minutes and clot area was analyzed using ImageJ. Representative pictures are shown on
the right. Measured clot area is presented on the right; n = 3. (F) Whole blood of GARP cKO mice and GARP+/+ littermates was perfused over a Horm
collagen (100 μg/mL) coated coverslip at a shear rate of 1600 s-1. Thrombus formation was visualized during 5 min and surface coverage was
quantified using ImageJ; n = 3. Representative pictures of thrombus formation under flow are shown on the right; scale bars represent 50 μm.
doi:10.1371/journal.pone.0173329.g003
GARP in thrombosis
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and littermates (Fig 4C; quantification on left, representative images on right). In both the
carotid and the mesenteric artery thrombosis model, no differences were observed in emboli-
zation or clot stability between GARP cKO mice and littermates.
Fig 4. Unaltered bleeding time and thrombus formation in Pf4 specific GARP cKO mice. (A) 2 mm of the tail tip was dissected
and tail bleeding times were measured (n = 10). (B) Carotid artery was injured using topical application of 12% FeCl3 and blood flow
was monitored using a flow probe until flow stopped due to the formation of an occlusive thrombus (n = 10). (C) Mesenteric arteries
were injured using 10% FeCl3 and thrombus formation was followed using intravital microscopy until full occlusion was reached
(n = 10). Representative pictures after 5, 8 and 10 min of mesenteric thrombus formation are shown on the right. Scale bars represent
50 μm. (D) The right middle cerebral artery of littermate mice (n = 14) and platelet specific GARP knockout mice (n = 12) was occluded
during 60 min and reperfusion was allowed during 23 hours.
doi:10.1371/journal.pone.0173329.g004
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Platelets play a major role in stroke progression and platelet receptors such as GPIb and
GPVI are known to be involved in the thrombo-inflammatory process [23]. To investigate
whether GARP on platelets contributes to the ischemia/reperfusion process, the tMCAO
model was performed in littermate and platelet specific GARP knockout mice. The infarct vol-
umes after 60 min of tMCAO and 23 hours of reperfusion were measured but did not differ
(Fig 4D). Together, these results are in line with the ex vivo results, and all together indicate
that GARP expressed on platelets is neither required for thrombosis, hemostasis nor thrombo-
inflammation.
GARP is expressed on mouse endothelium and is absent on Tie2
specific GARP knockout mice
Overall, our results demonstrate that a deficiency of GARP on mouse platelets does not affect
thrombus formation and therefore could not explain the thrombotic phenotype observed in
the GARP deficient zebrafish. We therefore generated endothelium specific GARP knockout
mice as GARP is also highly expressed on human endothelial cells [3]. Moreover, endothelial
cells are important in the formation and stabilization of thrombi as they express amongst oth-
ers adhesion receptors and secrete von Willebrand factor, but also limit platelet activation by
formation of PGI2 and NO.
First, GARP expression on murine endothelial cells was measured. Single liver cells were
isolated and incubated with antibodies against CD31 (endothelial marker), CD45 (leukocyte
marker) and CD41 (platelet marker), as well as antibodies against GARP. As shown in Fig 5A,
GARP indeed is expressed on murine CD31+CD45-CD41- endothelial cells. Isotype matched
antibodies were used as a negative control for the anti-GARP monoclonal antibodies and dem-
onstrated no positive staining. The genotyping of C57BL/6 mice, littermates and endothelial
specific GARP knockout mice demonstrates the presence of loxP sites (181 bp) and the Cre
recombinase (450 bp) in the genomic DNA (Fig 5B). Correct recombination was confirmed by
demonstrating the absence of GARP on CD31+CD45-CD41- single endothelial liver cells by
flow cytometry (Fig 5A). This confirms the successful generation of Tie2 specific GARP knock-
out mice. The mice were born at the expected Mendelian frequencies, showed no discernable
phenotype, were fertile and the body weights were comparable between the endothelial specific
GARP knockout mice and littermate controls.
Endothelial GARP is not important in thrombus formation or thrombo-
inflammation
Similar to the platelet specific GARP cKO mice, the tail bleeding time did not differ between
the endothelium specific GARP cKO and the littermates (Fig 6A). In the carotid artery, occlu-
sive thrombus formation was monitored and both littermates and GARP cKO mice did form
occlusive thrombi at a similar rate (Fig 6B). Accordingly, complete mesenteric artery occlusion
was comparable for the GARP cKO mice and littermates (Fig 6C; quantification on left, repre-
sentative images on right). In both the carotid and the mesenteric artery thrombosis model, no
differences were observed in embolization or clot stability between GARP cKO mice and litter-
mates. To investigate whether GARP on endothelial cells contributes to the ischemia/reperfu-
sion process, the tMCAO model was performed in littermate and endothelium specific GARP
knockout mice. The infarct volumes after 60 min of tMCAO and 23 hours of reperfusion were
comparable for the endothelium specific GARP knockout mice and controls (Fig 6D). In con-
clusion, these results strongly suggest that GARP expressed on murine platelets as well as on
murine endothelial cells is neither important for thrombosis, hemostasis nor thrombo-
inflammation.
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Discussion
Thrombus formation is a dynamic process in which platelet receptors and components of the
endothelium play a crucial role in the adhesion, aggregation and stabilization of the growing
thrombus. A comparative transcript study identified 279 novel platelet membrane receptors of
which ESAM, BAMBI, DCBLD2, GARP and ANTXR2 were selected for further investigation
in zebrafish (with αIIb as a positive control) [3]. In the zebrafish study, the targeted gene was
completely down regulated in the whole genome by applying antisense morpholino oligonu-
cleotides. Based on the effects seen in a laser induced thrombosis model in the caudal artery of
the respective gene deficient zebrafish, a function for all but ANTXR2 membrane receptors in
thrombosis was proposed. However, as the different receptors are not only expressed in the
megakaryocyte lineage, but also on e.g. endothelial cells, some types of leukocytes and erythro-
blasts, the relevant cell responsible for the effect in thrombosis was not defined. Therefore,
there is a need for follow-up studies in which the targeted gene is selectively removed from
specific cells. In the zebrafish study, BAMBI was identified as a positive regulator of thrombo-
sis. Salles-Crawley et al. further investigated its function in thrombosis and hemostasis using
chimeric mice. The previously observed results in zebrafish were confirmed [15], with a
Fig 5. Generation of endothelial specific GARP knockout mice. (A) Phenotypic characterization of littermates and cKO mice using flow
cytometry. Single cells were labeled with anti-CD45-PeCy7, anti-CD31-PE, anti-CD41-FITC and anti-GARP-APC and a histogram was made
based on APC intensity of CD45-CD31+CD41- population. Isotype control (black line), littermates (grey line) and cKO (black). (B) Genotypic
analysis of genomic DNA from control C57BL/6, littermates and endothelial specific cKO mice. Loxp is 181 bp (fl/fl); wt allele is 111 bp, Cre 450
bp.
doi:10.1371/journal.pone.0173329.g005
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thrombus-stabilizing role for BAMBI expressed in endothelium whereas platelet BAMBI has
no role in thrombosis and hemostasis. Also the contribution of ESAM, suggested to be a
Fig 6. Unaltered bleeding time and thrombus formation in Tie2 specific GARP cKO mice. (A) 2 mm of the tail tip was dissected
and tail bleeding times were measured (controls: n = 11; cKO: n = 9). (B) Carotid artery was injured using topical application of 12%
FeCl3 and blood flow was monitored using a flow probe until flow stopped due to the formation of an occlusive thrombus (controls:
n = 10; cKO: n = 11). (C) Mesenteric arteries were injured using 10% FeCl3 and thrombus formation was followed using intravital
microscopy until full occlusion was reached (controls: n = 10; cKO: n = 11). Representative pictures after 5, 8 and 10 min of mesenteric
thrombus formation are shown on the right. Scale bars represent 50 μm. (D) The right middle cerebral artery of littermate mice (n = 10)
and endothelium specific GARP knockout mice (n = 16) was occluded during 60 min and reperfusion was allowed during 23 hours.
doi:10.1371/journal.pone.0173329.g006
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negative regulator of thrombus formation in zebrafish, was further elucidated. A mouse study
confirmed the function of ESAM in thrombus growth and stability, and herein suggests a criti-
cal role for platelet ESAM [24]. In the current study, we set out to determine whether GARP
would affect thrombus formation in mice. As full Garp knockout mice had an embryonic lethal
phenotype, we generated both platelet and endothelium specific GARP knockout mice. The
expression of GARP on human platelets [3,6] and endothelial cells (3) was already reported
previously and we now demonstrated that GARP is also expressed on murine platelets and
endothelium.
Platelet specific GARP knockout mice were generated, allowing comprehensive assessment
of GARP deficiency on platelets. No differences were measured in ex vivo α-granule release,
platelet adhesion, spreading and clot retraction. However, a significantly decreased integrin
αIIbβ3 activation was measured in GARP cKO platelets after activation with CRP. Neverthe-
less, this small difference in activation did not influence the other more physiological integrin
αIIbβ3 related ex vivo assays as no differences were observed in fibrinogen binding, platelet
spreading, clot retraction and aggregation. Accordingly, in vivo tail bleeding time or the time
to occlusion of the carotid or mesenteric artery after FeCl3-induced thrombosis and the
tMCOA stroke model did not show any difference between platelet specific GARP cKO mice
and littermate controls. Furthermore similar results were obtained in the endothelium specific
GARP knockout mice, strongly indicating that neither platelet nor endothelial GARP is
involved in thrombosis and hemostasis.
The hypothesis of this study was based on the functional screening of putative novel platelet
membrane proteins from the comparative whole-genome expression analysis by the induction
of arterial thrombosis following morpholino oligonucleotide knockdown in zebrafish [3]. The
zebrafish is a well-characterized animal model to study human disease phenotypes, more spe-
cifically in the field of megakaryopoiesis and hemostasis due to the high conservation of plate-
let functions such as thrombocyte adhesion and aggregation. Therefore the zebrafish was
postulated to be a good functional model to select genes involved in thrombosis [25–27]. The
results demonstrated that the two tested morpholinos used to downregulate GARP in zebrafish
gave diverse results in both time to adhesion and the surface area of the thrombus formed after
laser injury of the caudal artery. Moreover, negative control morpholinos did not demonstrate
similar results between the different investigated receptors [3]. Therefore, further investigation
using murine thrombosis models was necessary to clarify these results. In this study, knocking
out GARP specifically in mouse platelets or endothelial cells could not confirm the positive
thrombus regulating phenotype of GARP in zebrafish. This inconsistency may be explained by
the variation measured in the zebrafish study or by differences between zebrafish and mouse
species. Zebrafish thrombocytes are nucleated, the GPIb receptor is differently expressed in
zebrafish and downregulation of other proteins in zebrafish, such as hepsin using morpholino
oligonucleotides also resulted in inconsistent results with the gene knockout in mice [28].
Taken together, this indicates that thrombosis models in zebrafish are not always a good pre-
dictor for gene function in mice.
In this study, we showed that the GARP full knockout mice were not viable, but endothe-
lium and platelet specific conditional GARP knockout mice were born and did not show any
overt phenotype. Also CD4 T cell specific GARP knockout mice [14] and Foxp3 specific
GARP knockout mice (unpublished results) were demonstrated to be viable. This suggests that
GARP may be involved in the mouse embryonal development by its ability to bind latent
TGF-β [6,8,14,29]. This however, is beyond the scope of our current study.
An alternative role for GARP was found in the release of active TGF-β [30]. On human
platelets, co-expression of GARP and the latency associated peptide, which noncovalently asso-
ciate with mature dimeric latent TGF-β, was reported [6,29]. The α-granules of platelets are
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the major source of latent TGF-β, a cytokine which is released upon platelet activation. Although
most of the released latent TGF-β is bound to the latent TGF-β binding protein and contributes
to the TGF-β1 levels in the circulation, 40% of the latent TGF-β is present in a platelet-rich
thrombus [31–33]. The specific contribution of TGF-β to thrombus formation however, is not
thoroughly elucidated. TGF-β by itself does not induce platelet aggregation [32,34], but seems to
have a slightly activating effect when used in combination with different platelet agonists, such as
collagen, U46619, ADP and SFLLRNP [34,35]. As Cuende et al. showed that inhibitory anti-
GARP antibodies can block the release of active TGF-β on Treg, GARP may also be involved in
the gradual release of active TGF-β on platelets and endothelium [11]. Consequently, GARP
may be involved in the targeted delivery of TGF-β in wound repair, in particular in angiogenesis.
Further studies will have to elucdiate the potential role of platelet or endothelium GARP in these
processes.
Supporting information
S1 Fig. Full GARP knockout mice are not viable. Mice with the Cmv promotor driven Cre
recombinase were crossed with Garpfl/fl mice in the first generation. Garpfl/-Cre+/- mice were
backcrossed with Garpfl/fl mice to generate full Garp knockout mice. (A) Genotypic analysis of
genomic DNA from neonates from the second generation, Floxed allele is 670 bp (fl/fl); WT
allele is 610 bp, Cre 200 bp. WT: wild type, Floxed: Garp allele is surrounded by Loxp sites,
Loxp: Garp allele is deleted and 1 Loxp site remains (B) percentage born neonates are given for
each possible genotype.
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